1. Development of a pathogenesis‐based therapy for peeling skin syndrome type 1*. (1st June 2021) Authors: Valentin, F.; Wiegmann, H.; Tarinski, T.; Nikolenko, H.; Traupe, H.; Liebau, E.; Dathe, M.; Oji, V. Journal: British journal of dermatology Issue: Volume 184:Number 6(2021) Page Start: 1123 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Development of a pathogenesis‐based therapy for peeling skin syndrome type 1. (1st June 2021) Authors: Valentin, F.; Wiegmann, H.; Tarinski, T.; Nikolenko, H.; Traupe, H.; Liebau, E.; Dathe, M.; Oji, V. Journal: British journal of dermatology Issue: Volume 184:Number 6(2021) Page Start: 1123 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Development of a pathogenesis‐based therapy for peeling skin syndrome type 1. (2nd November 2020) Authors: Valentin, F.; Wiegmann, H.; Tarinski, T.; Nikolenko, H.; Traupe, H.; Liebau, E.; Dathe, M.; Oji, V. Journal: British journal of dermatology Issue: Volume 184:Number 6(2021) Page Start: 1123 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. LEKTI domains D6, D7 and D8+9 serve as substrates for transglutaminase 1: implications for targeted therapy of Netherton syndrome. (1st November 2019) Authors: Wiegmann, H.; Valentin, F.; Tarinski, T.; Liebau, E.; Loser, K.; Traupe, H.; Oji, V. Journal: British journal of dermatology Issue: Volume 181:Number 5(2019) Page Start: 999 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. LEKTI domains D6, D7 and D8+9 serve as substrates for transglutaminase 1: implications for targeted therapy of Netherton syndrome. (6th June 2019) Authors: Wiegmann, H.; Valentin, F.; Tarinski, T.; Liebau, E.; Loser, K.; Traupe, H.; Oji, V. Journal: British journal of dermatology Issue: Volume 181:Number 5(2019) Page Start: 999 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Refining the dermatological spectrum in primary immunodeficiency: mucosa‐associated lymphoid tissue lymphoma translocation protein 1 deficiency mimicking Netherton/Omenn syndromes. (1st January 2020) Authors: Wiegmann, H.; Reunert, J.; Metze, D.; Marquardt, T.; Engel, T.; Kunde, V.; Ehl, S.; Foell, D.; van den Heuvel, I.; Oji, V.; Wittkowski, H. Journal: British journal of dermatology Issue: Volume 182:Number 1(2020) Page Start: 202 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Refining the dermatological spectrum in primary immunodeficiency: mucosa‐associated lymphoid tissue lymphoma translocation protein 1 deficiency mimicking Netherton/Omenn syndromes. (21st July 2019) Authors: Wiegmann, H.; Reunert, J.; Metze, D.; Marquardt, T.; Engel, T.; Kunde, V.; Ehl, S.; Foell, D.; van den Heuvel, I.; Oji, V.; Wittkowski, H. Journal: British journal of dermatology Issue: Volume 182:Number 1(2020) Page Start: 202 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗